Ignite Creation Date:
2025-12-26 @ 2:39 PM
Ignite Modification Date:
2026-06-13 @ 10:09 PM
Study NCT ID:
NCT00700206
Status:
COMPLETED
Last Update Posted:
2011-10-12
First Post:
2008-06-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Sponsor:
Telik
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myelodysplastic Syndrome (MDS) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hematology | View |
| None | MDS | View |
| None | Myelodysplastic Syndrome | View |
| None | Low Risk MDS | View |
| None | Intermediate-1 risk MDS | View |
| None | Int-1 risk MDS | View |
| None | Telintra | View |
| None | ezatiostat hydrochloride | View |
| None | ezatiostat | View |
| None | TLK199 | View |
| None | Glutathione | View |
| None | Glutathione analog | View |
| None | Glutathione Transferase | View |
| None | Glutathione Transferase inhibitor | View |
| None | Glutathione Transferase P1-1 inhibitor | View |
| None | GSTp1-1 inhibitor | View |
| None | Apoptosis | View |
| None | Differentiation | View |
| None | Enzyme inhibitor | View |